Breast Cancer Clinical Trial
Official title:
Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Verified date | January 2018 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
formulation, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Giving paclitaxel albumin-stabilized
nanoparticle formulation together with pemetrexed may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel
albumin-stabilized nanoparticle formulation when given together with pemetrexed and to see
how well they work in treating patients with advanced non-small cell lung cancer, breast
cancer, or other solid tumors.
Status | Terminated |
Enrollment | 49 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria 1. For the phase II portion patients must have cytologically or histologically proven selected stage IIIB (pleural effusion) or IV NSCLC. 2. For the phase II portion patients must have NSCLC that has progressed or recurred after treatment with platinum-based therapy. 3. No prior pemetrexed. Prior Taxol is allowed. Prior ABI 007 is not allowed. 4. Patients must have measurable disease by RECIST criteria for the phase II portion. 5. Patients must be 18 years of age or older. 6. Patients must have a performance status of 0 -2 7. Patients must have an estimated survival of at least 3 months. 8. Any prior chemotherapy must have been completed at least 4 weeks prior to start of treatment. 9. Patients must have adequate renal function as documented by a calculated creatinine clearance of > 45 ml/min 10. Patients must have adequate liver functions: AST and ALT < 2.5 X upper limit of normal, and bilirubin < upper limit of normal. 11. Patients must have adequate bone marrow function: Platelets >100,000 cells/mm3 and ANC > 1,500 cells/mm3. 12. For patients who have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing. 13. Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) may be included if they are neurologically stable and have been off steroids and anticonvulsants for at least 4 weeks. 14. Patients must be able to take and retain oral medication. 15. Ability to take folic acid, vitamin B12 and dexamethasone according to protocol. 16. Ability to interrupt NSAIDS 2 days before, the day of, and 2 days following administration of pemetrexed. 17. Patients of reproductive potential must agree to use effective contraceptive method while on treatment and for 3 months afterwards as the effects of these drugs on the unborn fetus are unknown. 18. No other current active malignancy. 19. Patient or his/her legally authorized representative or guardian signed the Informed Consent form prior to participation in any study-related activities. Exclusion Criteria 1. Pregnant or breastfeeding women. 2. Patient with pre-existing peripheral neuropathy of NCI CTCAE Version 3.0 of grade 2. 3. Patient has a clinically significant concurrent illness. 4. Patient is currently enrolled in a different clinical study in which investigational procedures are performed or investigational therapies are administered. 5. Patient has a history of allergy or hypersensitivity to the study drugs or a taxane. 6. Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug. 7. Prior therapy with pemetrexed, or ABI-007. 8. Patient is receiving treatment with any excluded concomitant medication. 9. Presence of third space fluid which cannot be controlled by drainage. |
Country | Name | City | State |
---|---|---|---|
United States | University of California Davis Cancer Center | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis | Celgene, Eli Lilly and Company |
United States,
Ho C, Davies AM, Sangha RS, Lau D, Lara P Jr, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec;31 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Dose Limiting Toxicities | Dose limiting toxicity (DLT) was defined as any of the following occurring during the first cycle: Grade 4 thrombocytopenia, or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion, febrile neutropenia, neutropenia with documented infection. Non-hematologic DLT included any other = grade 3 non-hematologic toxicity that was clinically significant and considered by the investigator to be related to study drug. Alopecia and grade 3 allergic reaction/hypersensitivity with infusion were not considered DLTs. | Up to21 days | |
Primary | Number of Patients With Toxicities | Toxicities was evaluated based on the standard NCI CTCAE Version 3.0 grading criteria. Attributable grade = 3 hematologic and non-hematologic toxicities are presented here. | Up to 1 year | |
Secondary | Duration of Overall Survival | From time of enrollment to the first observation of disease progression or death. | Up to 2 years | |
Secondary | Number of Participants With Complete Response | Per RECIST criteria, complete response (CR) is defined as the disappearance of all target lesions. | Up to 2 years | |
Secondary | Number of Participants With Stable Disease | Stable Disease is measured from the start of the treatment until the criteria for disease progression are met. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions | Up to 2 years | |
Secondary | Number of Participants With Partial Response | At least a 30% decrease in the sum of the longest diameter of target lesions | Up to 2 years | |
Secondary | Number of Participants With Disease Control | Disease control is complete response plus partial response plus stable disease from the start of treatment to death or disease progression. | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |